enabling them to better make informed decisions. Women who are trying to become pregnant or who are pregnant should avoid travel to areas with active Zika virus transmission and, if they must travel, should talk to their healthcare provider first and take steps to minimize exposure to Zika virus. Furthermore, women who are trying to become pregnant should follow Centers for Disease Control and Prevention (Atlanta, GA, USA) guidelines on how long to wait to get pregnant after a potential Zika virus exposure (7). Women who want to avoid pregnancy and their male partners should use effective birth control correctly and consistently (8). Healthcare providers in the United States caring for pregnant women and women who are trying to become pregnant should routinely discuss travel history and travel plans with their patients.

Acknowledgments

We thank all women who participated in the survey for their cooperation and DOHMH staff involved with the Zika Testing Call Center.

Ms. Whittemore is an Emerging Infectious Disease Epidemiologist at the New York City Department of Health and Mental Hygiene. Her primary research interests are in vaccine-preventable diseases, emergency management, and access to healthcare.

References


Address for correspondence: Neil M. Vora, New York City Department of Health and Mental Hygiene 42-09 28th St, Long Island City, NY 11101, USA; email: nvora@cdc.gov

Multidrug-Resistant Pathogens in Hospitalized Syrian Children

Diana Faour Kassem, Yoav Hoffmann, Naama Shahar, Smadar Ocampo, Liora Salomon, Zeev Zonis, Daniel Glikman

Author affiliations: Galilee Medical Center, Nahariya, Israel (D. Faour Kassem, Y. Hoffmann, N. Shahar, S. Ocampo, L. Salomon, Z. Zonis, D. Glikman); Bar-Ilan University, Safed, Israel (Y. Hoffmann, D. Glikman)

DOI: http://dx.doi.org/10.3201/eid2301.161204

Since 2013, wounded and ill children from Syria have received treatment in Israel. Screening cultures indicated that multidrug-resistant (MDR) pathogens colonized 89 (83%) of 107 children. For 58% of MDR infections, the pathogen was similar to that identified during screening. MDR screening of these children is valuable for purposes of isolation and treatment.

As the civil war in Syria enters its sixth year, the United Nations estimates that ≈250,000 persons have been killed, ≈10,000 of them children (1). Preliminary reports indicate a high rate of multidrug-resistant (MDR) pathogen carriage among refugees from Syria, mostly adults (2–5). Preliminary data for 29 wounded Syrian children indicate that 66% carried extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL) (2).

For ≈3 years, Syrian children who were ill or severely wounded from the civil war have been secretly transported across the border for treatment in Israel, mainly at Galilee Medical Center (GMC; Nahariya, Israel). We characterized carriage of and infections with MDR pathogens among these children.

We prospectively collected demographic and clinical microbiology data for all Syrian children 0–17 years of age who were admitted to GMC during March 2013–February 2016. At admission, contact isolation and screening cultures for MDR were conducted. MDR pathogens belonged to 1 of 5 groups: ESBL, carbapenem-resistant Enterobacteriaceae (CRE), methicillin-resistant Staphylococcus aureus, MDR Acinetobacter baumannii (MDR-AB), and vancomycin-resistant Enterococcus. Culture sites included nares, axilla, groin, rectum, and open wounds. Bacterial identification and susceptibility testing were performed according to Clinical and Laboratory Standards Institute guidelines (http://clsi.org/standards/micro/). For CRE screening, we used CHROMagar plates (hylabs, Rehovot, Israel).
The mechanism of CRE resistance was determined by the GeneXpert Carba-R system (Cepheid, Sunnyvale, CA, USA) with PCR. For MDR-AB screening, we used MacConkey plates with ceftriaxone disks. The study was approved by the GMC institutional review board.

During the study period, 128 Syrian children were admitted to GMC; 92 (72%) were male, median age was 11 (0–17) years, and 87 (68%) were treated for multiple trauma and 41 (32%) for acute or chronic illness. Average hospitalization length was 1 month. Because of trauma severity, 4 (3%) died at arrival.

Of the 128 children, screening cultures for all 5 pathogen groups were performed for 107, and these children were included in the study (Figure). MDR pathogen carriage was found for 89 (83%). Among MDR pathogens carried, all 5 groups were represented. Among CRE, the most common resistance mechanism was New Delhi metallo-β-lactamase. Rates of MDR carriage were similar among wounded and ill children, mean MDR carriage rate among children increased from 1.19 in 2013–2014 to 1.45 in 2015 (p = 0.02). No amikacin resistance to ESBL was detected. Colistin was the only drug to which CRE and MDR-AB were susceptible.

For 24 (19%) children, MDR infections were evident, mostly urinary tract, surgical site, and osteomyelitis. Infections were more frequent among wounded (90%) than among sick (10%) children (p = 0.035). Two thirds of infections were caused by ESBL, 20% by MDR-AB, and 15% by CRE. In 58% of children with infections, the infecting isolate was similar (by species and antimicrobial drug susceptibility) to the MDR pathogen identified by screening. The empirically prescribed therapy for sepsis was meropenem and amikacin. Colistin was empirically added for severe sepsis or colonization with CRE or MDR-AB.

The rate of MDR carriage among wounded and ill Syrian children who were treated in Israel is extremely high. This finding probably implies a high carriage rate of MDR pathogens (especially ESBL) among healthy children in Syria and acquisition of MDR pathogens (especially CRE and MDR-AB) in the healthcare system in Syria. Indeed, before the Syrian war, prevalence of ESBL urinary tract infections associated with wide use of antimicrobial drugs was high (6). In addition, sale of antimicrobial drugs without prescriptions was common in Damascus and other areas (7). The war added inadequate sanitation, hospital and infrastructure destruction, and suboptimal infection control measures. Increased rates of MDR pathogen carriage in 2015, compared with 2013–2014, along with the recent polio and measles outbreaks, suggest further deterioration of the healthcare system in Syria (8).

Neighboring countries and European centers (for healthcare and asylum seekers) report finding MDR pathogens among wounded adult patients and refugees from Syria; in Germany, among refugees from Syria in 2016, the rate of colonization with gram-negative MDR pathogens was 60% (3–5,9). Earlier in the Syrian conflict, we described an MDR pathogen carriage rate of 66% (almost all ESBL) among 29 children in Israel (2).

Since then, many more Syrian children have been treated at GMC. Approximately 80% of these children are colonized by MDR pathogens; ESBL predominate, followed by CRE and MDR-AB.

Our data, relevant to other centers caring for patients from Syria, show that contact isolation at the time of admission of patients from Syria is crucial for preventing transmission of MDR pathogens. We did not observe cross-infections, but another center in Israel that cares for patients from Syria has documented nosocomial spread of oxacillinase-48 CRE (10). Thoughtful decisions about empiric antimicrobial drug therapy for patients from Syria suspected of having infection are complex, given the multitude of MDR pathogens carried and the severity of trauma. Our study demonstrates that in almost 60% of MDR infections, the pathogen was similar to that found on screening cultures. Therefore, screening cultures at admission can provide valuable information for infection control, isolation decision-making, and tailoring appropriate empiric antimicrobial drug therapy.
Acknowledgment
We thank Tobie Kuritsky for assistance with manuscript preparation.

Dr. Faour Kassem is a resident I pediatric physician at Galilee Medical Center, Nahariya, Israel.

References

Address for correspondence: Daniel Glikman, Pediatric Infectious Diseases Service, Galilee Medical Center, PO Box 21, Nahariya, 22100, Israel; email: danny.glikman@naharia.health.gov.il; dannytamar@gmail.com